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Abstract 
In order to provide specificity for T cell responses against pathogens and tumours, MHC 
class I molecules present high-affinity peptides at the cell surface to T cells. A key player for 
peptide loading is the MHC class I-dedicated chaperone tapasin.  Recently we discovered a 
second MHC class I-dedicated chaperone, the tapasin-related protein TAPBPR.   Here, we 
review the major steps in the MHC class I pathway and the TAPBPR data. We discuss the 
potential function of TAPBPR in the MHC class I pathway and the involvement of this 
previously uncharacterised protein in human health and disease.  
 
Keywords: TAPBPR/TAPBPL, tapasin, antigen processing and presentation, MHC, human, 
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INTRODUCTION 
The presentation of small peptide fragments on MHC class I molecules allows the peptidome 
of an individual cell to be conveyed to the immune system.  In this way, MHC class I 
molecules act as a critical detection system of both pathogenic infection and cellular 
transformation. Delineating the mechanisms that underlie peptide selection by MHC class I 
molecules is of crucial importance for all aspects of immune recognition from infection 
control and tumour surveillance, to transplant rejection and susceptibility to auto-
inflammatory conditions.   Over the past 25 years, immense progress has been made in 
identifying a number of key stages and important players involved in the generation of 
peptide:MHC complexes. Due to the significant progress already made and the complexity of 
the pathway, there is perhaps a general misconception that our knowledge of the antigen 
processing and presentation pathway is complete. This is simply not the case. The molecular 
mechanisms controlling MHC peptide selection for immune recognition still have many 
secrets to reveal. In this review we give an overview of the major known molecular players 
involved in the loading of peptide onto MHC class I molecules, recount our recent 
identification of TAPBPR as a new MHC class I specific chaperone, then discuss the 
potential role of TAPBPR in the antigen presentation pathway.  
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THE MHC I ANTIGEN PROCESSING AND PRESENTATION PATHWAY 
The cell biology of MHC class I molecules has already been elegantly and extensively 
reviewed in this journal in 2010 (1).  Thus, we will only give a brief overview here of the 
major molecular players known to that date (Figure 1).  
 
THE CLASSICAL ROUTE OF ANTIGEN PRESENTATION 
Peptide generation and delivery into the ER 
Peptides for presentation on MHC class I by the classical presentation pathway are generated 
by proteasomal degradation of proteins in the cytosol. Although the relative contribution of 
different peptide sources is still a matter of debate, peptides can originate from the natural 
degradative turnover of self-proteins, proteins over-expressed as a result of malignant 
transformation, defective ribosomal products of protein translation and peptides derived from 
infection by intracellular parasites such as viruses (2-4). A further source of antigenic 
peptides is the pioneer round of mRNA translation and nuclear translation (5, 6). 
Furthermore, the cellular machinery may use the unconventional CUG Start Codon to initiate 
protein synthesis for antigen presentation on MHC class I molecules (7).  
Peptides are then transported into the lumen of the ER by the transporter associated with 
antigen processing (TAP).  This complex is a heterodimer composed of TAP1 and TAP2 and 
belongs to the ATP-binding cassette (ABC) transporter family, responsible for mediating 
transport of substrates across membranes in an ATP-dependent manner (8-10). The 
importance of TAP in the MHC class I pathway is seen in TAP-deficient cells, in which 
MHC class I cell surface expression is severely reduced and degradation of MHC class I 
molecules is increased (11-13). 
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Peptide trimming in the ER 
After translocation into the lumen of the ER, peptides are typically longer than peptides that 
finally bind to mature MHC class I molecules and therefore require further trimming. The 
endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP in mice, 
ERAP1/2 in humans) is responsible for trimming N-terminal extended precursor peptides in 
the ER (14, 15). Recently, it has been shown that ERAP1 and ERAP2 form dimers and this 
dimerization produces allosteric effects on ERAP1 that enhance peptide trimming efficiency 
significantly (16).  The importance of ERAAP function in the presentation of peptides to T 
cells is evident from studies using ERAAP depleted cells in which decreased cell surface 
expression of MHC class I molecules and impaired presentation of antigenic peptides to T 
cells is observed (14, 15, 17). The peptide repertoire is significantly altered in ERAAP-/- 
mice, in which both a loss, as well as gain, of new peptide/MHC I complexes is observed 
(18). An unresolved issue is whether precursor peptides first bind to MHC class I molecules 
and are then trimmed by ERAAP, or if trimming happens before peptides bind to MHC class 
I. 
 
Early MHC class I folding events 
The type I transmembrane protein calnexin, together with its soluble homologue calreticulin, 
mediate the folding of nascent glycoproteins in the ER, including the MHC class I heavy 
chain which is glycosylated at Asn-86 (Figure 1).  Both calnexin and calreticulin work 
together with the protein disulphide isomerase ERp57, which assists with disulphide bond 
formation within the membrane-proximal α3 domain of the MHC class I heavy chain (19-22).  
After initial folding, assisted by calnexin, the MHC class I heavy chain associates with β2-
microglobulin and subsequently associates with calreticulin (23, 24). 
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The peptide loading complex and the central role of tapasin 
At this point the MHC class I heavy chain is integrated into the peptide loading complex 
(PLC), a multiprotein complex in which the MHC class I molecules are loaded with peptides. 
The PLC consists of TAP, the lectin-like chaperone calreticulin, the MHC class I dedicated 
chaperone tapasin, and the thiol reductase ERp57 (Figure 1). Although protein disulphide 
isomerase (PDI) has also been reported to associate with the PLC (25), these results remain to 
be confirmed by other groups (26-28). 
 
Molecular associations governed by tapasin 
Tapasin forms the centre-piece of the PLC as it facilitates a number of molecular associations 
which assemble the multi-protein complex. First, tapasin binds to peptide-receptive MHC 
class I heterodimers (24). Currently, two distinct associations between the two molecules are 
thought to occur: a cluster of conserved residues in the N-terminal domain of tapasin contact 
a loop below the 2-1 helix of the MHC class I, while residues in the membrane proximal Ig-
like domain of tapasin associate with a -strand in the 3 domain of MHC class I (29). 
Second, tapasin binds to the TAP transporter (24). This interaction, which is dependent on a 
positively charged residue in tapasin’s transmembrane domain, bridges the peptide-receptive 
MHC class I molecules to the TAP transporter, thus localising the MHC class I heterodimer 
at the peptide source (24, 30, 31).  This association also stabilises TAP, resulting in enhanced 
TAP levels and increased translocation of peptides into the ER (32).  Third, tapasin binds to 
ERp57 via an intermolecular disulphide bridge between C95 of tapasin and C57 in ERp57 
(26, 33). This association is essential for the structural stability of the PLC and therefore is 
essential for optimal peptide loading of MHC class I molecules (33, 34). Other subsequent 
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associations known to occur in the PLC are an interaction of ERp57 with the P-domain of 
calreticulin, which acts as a bridge between calreticulin and tapasin (20), and an association 
of the monoglucosylated glycan of MHC class I with calreticulin (35). These calreticulin-
dependent associations are also essential for PLC activity (36, 37). Thus the molecular 
associations centred round tapasin provide strength and stability to interactions within the 
PLC which otherwise would be characteristically weak and transient.  
 
Therefore, tapasin is crucial for the production of a functional PLC (34). In the absence of 
tapasin, MHC class I assembly with TAP is impaired and MHC class I molecules are 
inefficiently loaded with peptide. Consequently cell surface expression of conformational 
MHC class I is severely reduced (24, 30, 38, 39). In tapasin-/- mice cell surface expression of 
MHC class I molecules such as H2-Kb and H2-Db is decreased by at least 100-fold and the 
mice exhibit severely impaired CD8+ T cell immunity compared to wild type animals (38, 
39). Consequently, tapasin is crucial for optimal induction of T cell immunity. 
 
The role of tapasin in peptide editing 
An important function assigned to tapasin, crucial for the generation of optimal loaded and 
stable MHC class I-peptide complexes, is peptide optimisation or peptide editing (1, 40-42). 
This is achieved by promoting the replacement of low-affinity peptides with high-affinity 
peptides. The precise molecular mechanisms underpinning peptide editing are still unclear.  
In addition, the nature of the conformational changes in MHC class I molecules upon peptide 
binding remains unknown, as currently no structure of a peptide-receptive MHC class I 
molecule exists.  However a number of key concepts regarding peptide editing are 
uncontested and can be stated thus: (i) Peptide editing involves the replacement of sub-
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optimal, fast off-rate peptides by higher-affinity, slower off-rate peptides; (ii) Peptide editing 
is an intrinsic characteristic of MHC class I molecules; (iii) Tapasin is able to enhance this 
intrinsic characteristic of MHC class I molecules. This quality control for peptide binding is 
essential for the generation of an optimal T cell response (30) and is in some respects 
analogous to the HLA-DM molecule in MHC class II antigen presentation (43).  
 
Tapasin dependency of HLA allomorphs  
Over the last 18 years, many reports have demonstrated that polymorphism in HLA 
allomorphs result in MHC class I molecules exhibiting different dependences on tapasin to 
acquire peptides.  First, there is significant variability regarding incorporation of HLA 
allomorphs into the PLC, with most HLA-A allomorphs displaying efficient incorporation 
while the majority of HLA-B allomorphs are reported to be inefficiently incorporated (44-
46).  This phenomenon appears to be strongly influenced by the residue at position 116 in the 
α2 domain of the MHC class I heavy chain, with additional residues in the surrounding 
region, such as residue 156, also influencing the interaction. Second, there is significant 
variability regarding the ability of HLA allomorphs to be stably expressed at the cell surface 
in the absence of tapasin. At one end of the spectrum are the tapasin-dependent MHC 
allomorphs, which require tapasin in order to be stably expressed at the cell surface (for 
example HLA-B*44:02, HLA-A*A01, and B*08:01(47)). At the other end of the spectrum 
are the tapasin-independent MHC class I allomorphs (for example HLA-B*44:05, HLA-
A*02:01 and HLA-B*35:01) whose surface expression is relatively unaffected by the 
absence of tapasin (30, 48-51). These tapasin-independent MHC molecules are able to load 
and to modulate peptide cargo over time. Again, tapasin dependency is strongly influenced 
by the residue at position 116 in MHC class I. The classic example of this is observed with 
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subtypes of HLA-B44 which only differ at amino acid position 116. HLA-B*44:05 with a 
tyrosine at position 116 is tapasin-independent while HLA-B*44:02 with an aspartic acid at 
position 116 is tapasin-dependent (40, 52). The naturally occurring polymorphism in HLA-
B44 has been linked to both integration of MHC class I into the PLC and to tapasin-
dependent peptide optimisation (40, 52).  The residue at position 114 also contributes to 
tapasin dependency (53). It is important to note that tapasin-independent molecules are still 
acted upon by tapasin, and their peptide cargo is modulated by the presence of tapasin (54).  
 
Both molecular dynamics simulation studies and mathematical modelling of peptide selection 
are being used to understand why HLA allomorphs display different dependencies on tapasin 
for optimal peptide selection (55, 56). Data comparing HLA-B*44:02 and -B*44:05 suggest 
that tapasin-dependent allomorphs are more open and conformationally flexible than tapasin-
independent molecules. In the absence of tapasin, the α2-1 helix of tapasin-dependent MHC 
class I molecules is predicted to be partially unfolded and therefore unable to bind peptide.  
As a result, such MHC class I molecules require tapasin to become properly folded and 
thereby peptide-receptive (55).  Therefore, the dependency on tapasin to optimise peptide 
correlates with the intrinsic ability of different HLA allomorphs to maintain a ‘receptive’ 
conformation (1). This concept is further supported by the recent finding that tapasin-
dependent HLA-B allotypes exhibited lower refolding ability than tapasin-independent HLA-
B allotypes (51).  
 
UGT1 as a post-PLC quality control checkpoint 
Upon binding to a high-affinity peptide, the affinity between tapasin and the MHC class I 
molecule is reduced, releasing the MHC trimer from the PLC (57, 58). However, peptide-
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loaded MHC class I molecules do not exit the ER immediately but are retained in the ER 
once released from TAP (59-61). These findings raised the possibility of an additional MHC 
class I processing step after the PLC.  
 
In 2011, UDP-glucose glycoprotein glucosyltransferase (UGT1) was identified as an 
important molecular component of this post-PLC quality control checkpoint (62) (Figure 1). 
UGT1 is an ER/cis-Golgi resident enzyme which reglucosylates unfolded glycoproteins 
regenerating the Glc1Man9GlcNA2 moiety (for a review see (63)). This modification in turn 
sends the glycoprotein back into the calnexin/calreticulin cycle. In UGT1-deficient mouse 
embryonic fibroblasts surface expression of MHC class I is reduced, MHC class I maturation 
and assembly is delayed, and peptide selection is impaired (62). Furthermore, UGT1 appears 
to reglucosylate MHC class I molecules bearing suboptimal peptides and causes their re-
engagement with the PLC (36). Thus, UGT1 seems to detect suboptimally loaded MHC class 
I molecules and sends them back to the PLC. Interestingly, UGT1 serves also as a quality 
control checkpoint during CD1d assembly and shapes the lipid repertoire of newly 
synthesized CD1d (64), therefore it has a wider role in presentation of various antigens to 
immune cells. Precisely how UGT1 recognises conformational anomalies in its substrates is 
poorly understood (62). 
 
Anterograde trafficking of MHC class I molecule through the secretory pathway 
The mechanisms controlling the ER export of MHC class I molecules and their transport 
through the secretory pathway are rather enigmatic steps in the MHC class I antigen 
processing and presentation pathway. MHC class I molecules can be selectively sorted into 
ER exit sites (61).  ER exit signals have been identified in the cytoplasmic tail of MHC class 
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I molecules which sort the molecules into coat complex (COP)II coated vesicles (65-67). In 
addition, MHC class I molecules have been found to associate with the transport receptor 
BAP31 which contains an export motif (68-70). The relative contribution of these two 
mechanisms to the ER export of MHC class I is currently unknown and could reflect 
alternative fates of defined pools of MHC class I molecules.  There also appears to be a 
further bottleneck in the MHC class I pathway in the Golgi apparatus, supporting the idea that 
the quality control exerted by the MHC class I antigen processing and presentation pathway 
extends well beyond the ER (65, 66, 71).   Once the MHC class I heterotrimer traverses these 
various barriers, it travels to the cell surface to be monitored by circulating CTLs and NK 
cells.    
 
ALTERNATIVE PATHWAYS OF MHC CLASS I ANTIGEN PRESENTATION 
In addition to the classical MHC class I antigen processing and presentation pathway 
described above, alternative mechanisms can also contribute to the peptide repertoire 
presented to the immune system. These pathways have been discovered by characterisation of 
TAP-deficient cells, on which a pool of peptide epitopes named ‘T-cell Epitopes associated 
with Impaired Peptide Processing’ are presented by MHC class I molecules (72-75). These 
alternative peptides appear to stem from a variety of sources. A classic example is signal 
sequences liberated by signal peptidase and signal sequence peptidase (75, 76). The 
mechanism of peptide loading in the absence of TAP currently remains unknown.  One 
possibility is the existence of a second PLC, distinct from the tapasin/TAP complex. 
Alternatively, TAP-independent peptide loading of MHC class I could involve components of 
the MHC class II pathway such as the invariant chain, which exhibits a more prominent 
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association with MHC class I molecules in TAP deficient cells (77, 78).  Further research is 
needed to elucidate these alternative pathways of antigen presentation in detail. 
 
CROSS-PRESENTATION 
Cross-presentation is a second MHC I presentation pathway that occurs in Dendritic cells 
(DCs) involving the presentation of peptides from exogenous proteins, a process that is 
essential for triggering T-lymphocyte responses against infectious agents and tumours (79). 
The molecular mechanisms underlying cross-presentation remain elusive and the subject of 
intense investigation (for a comprehensive review see (80)). In general, three major pathways 
for cross-presentation have thus far been suggested, namely a cytosolic, a vacuolar and a 
phago-ER pathway. In the cytosolic pathway antigens are produced in the endosomes and 
transported into the cytosol via SEC transporters. These antigens can then enter the classical 
route of antigen presentation via TAP. The vacuolar pathway involves recycling of MHC 
class I from the cell surface.  MHC class I molecules can enter this pathway through 
endosomal compartments or possibly through the MIIC compartment where they are loaded 
with exogenous peptides. The process is guided by the tyrosine internalisation signal on the 
cytoplasmic tail of MHC class I molecules. It has been suggested that the MHC class II 
chaperone invariant chain (or CD74) is also involved in delivering a proportion of MHC class 
I molecules to such compartments for cross-presentation (77, 78, 81). Basha and colleagues 
have further highlighted the critical role of CD74 in cross-presentation of MHC class I 
molecules in vivo (82). The vacuolar pathway is known to occur in vivo for certain antigens. 
Another suggested route for cross-presentation is the ‘phago-ER’ (endoplasmic reticulum–
mediated phagocytosis) model, which was considered a dominant pathway of cross-
presentation. This pathway involves a fusion event between the ER and a phagosome. This 
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fusion event would allow enzymatic machinery, which is required for the release of 
phagosomal proteins into the cytosol to traffic to phagosomes. The validity of this route has 
been questioned. 
TAPBPR: AN ADDITIONAL MHC CLASS I SPECIFIC CHAPERONE IN THE 
ANTIGEN PROCESSING AND PRESENTATION PATHWAY 
In 2000, a human tapasin related gene (TAPBPL/TAPBPR) was identified on chromosome 
position 12p13.3 near an MHC paralogous locus (83).  Like tapasin, TAPBPR is an IFN- 
inducible, type I transmembrane protein consisting of three extracellular domains, a unique 
membrane distal domain, IgSF V domain and IgC1 domain (84-86)(Figure 2). In 2013, we 
showed that human TAPBPR shared tapasin’s ability to bind to MHC class I, a finding that 
was initially somewhat surprising, given that the two related molecules only share 
approximately 22% sequence identity (86). Both tapasin and TAPBPR appear to recognise a 
roughly similar form of MHC class I; an intracellular heavy chain/2m heterodimer which is 
peptide-receptive.  Through amino acid sequence alignment and homology modelling, we 
showed that the MHC class I binding site is conserved between tapasin and TAPBPR (Figure 
2), explaining the shared ligand, despite the large variability between the two proteins (29). 
 
TAPBPR is not simply a tapasin analogue. A number of functional disparities are clearly 
evident between of the two proteins even when simply comparing their amino acid sequence 
(Figure 2). For example, the charged residue in the TMD of tapasin, which is essential for its 
association with the TAP transporter (30, 31), is absent in TAPBPR. In addition, the ER 
retention motif in the cytoplasmic tail of tapasin (87) is not found in the tail of TAPBPR. In 
agreement with these observations, we found that, in contrast to tapasin, TAPBPR is not an 
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integral component of the peptide loading complex and its expression is not restricted to the 
ER (86).  Furthermore, TAPBPR does not bind to ERp57, despite having an unpaired 
cysteine residue in its extracellular domain (86). The differences between tapasin and 
TAPBPR are strikingly obvious when expression of the two related molecules is altered.  
TAPBPR over-expression in HeLa cells leads to a down-regulation of surface expression of 
conformational MHC class I, a phenotype resembling that of a tapasin-deficient cell (24, 30, 
38, 39, 86).  Therefore, it seems that, in these experiments at least, TAPBPR has an opposing 
function to that of tapasin. The lack of analogous function on MHC class I between tapasin 
and TAPBPR is further supported in TAPBPR deficient cells, in which no obvious 
phenotypic effect on conformational MHC class I expression is observed (86). This suggests 
that TAPBPR is not required for the initial peptide loading event, or is certainly not as crucial 
as tapasin for peptide loading.  
 
POTENTIAL FUNCTIONS OF TAPBPR IN THE MHC CLASS I PATHWAY 
For the past two decades tapasin was the only known MHC class I dedicated chaperone in the 
MHC class I antigen processing and presentation pathway.  The existence of TAPBPR has 
prompted a radical review of the whole process and some aspects of tapasin function will 
need to be re-evaluated.  But what is the actual function of TAPBPR in the MHC class I 
pathway? Although this is currently unknown, below we speculate on some possibilities and 
examine the current evidence for and against each suggestion (Figure 3). 
 
1. TAPBPR could represent a tapasin-independent pathway of antigen presentation in 
the secretory pathway 
15 
 
The first possibility to consider is that TAPBPR represents an independent folding pathway 
for MHC class I which runs alongside the classical antigen presentation pathway (Figure 3A). 
As highlighted above, TAPBPR is not simply a tapasin analogue, particularly since it is not 
an integral component of the PLC.  However, given the orientation of TAPBPR on MHC 
class I, it may share some functional properties of tapasin.  The positioning of tapasin on 
MHC class I is thought to be of critical importance for tapasin functioning as a peptide loader 
and editor.  As TAPBPR is orientated on MHC class I in a similar manner to tapasin, it is 
reasonable to suspect that it could also be involved in peptide loading and/or peptide editing 
on MHC class I.   
 
The orientation of TAPBPR on MHC class I in a similar way to tapasin may shed light on an 
old observation that has never been satisfactorily explained, namely why some MHC class I 
molecules can load peptides in a tapasin-independent manner. This tapasin-independence is 
likely to be highly influenced by the intrinsic characteristic of the specific MHC class I 
allomorph. That said, TAPBPR may also significantly influence the ability of certain MHC 
molecules (such as HLA-A2 and –B4405) to load peptides in the absence of tapasin.  In this 
respect, we would imagine that TAPBPR would need to share tapasin’s ability to load 
peptides.  But as TAPBPR is not an integral component of the PLC, what would be the nature 
of these TAPBPR-dependent peptides be?  Could TAPBPR be responsible for the TAP-
independent presentation pathway, loading the alternative peptide sources such as the ‘T-cell 
Epitopes associated with Impaired Peptide Processing’ described above? (74, 75). This idea 
may be supported by the fact that we found TAPBPR to bind more strongly, or to exhibit a 
more prolonged association, with HLA-A molecules such as HLA-A2 and HLA-A68, which 
are capable of loading signal sequences peptides, than with HLA-B molecules (29, 86).  In 
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what context would these TAPBPR-dependent sources of peptides be loaded onto MHC class 
I? As an isolated entity, or in complex with other molecules which constitute an alternative 
PLC in the ER? Intriguingly, TAPBPR has been identified as a leukocyte nuclear envelope 
transmembrane protein, which influences the positioning of genes/chromosomes in the 
nucleus (88).  An interesting speculation is that TAPBPR might be involved in antigenic 
peptide presentation from products generated directly in the nucleus, such as pioneer 
translational products (5, 6). 
 
However, the lack of any obvious phenotype of cell surface expression of MHC class I in 
TAPBPR depleted cells argues against a crucial role for the protein in the initial step of 
loading peptide onto MHC class I.  This lack of phenotype may occur due to redundancy in 
the MHC class I pathway; in the absence of TAPBPR, tapasin would load peptides onto 
MHC class I molecules, therefore there would be no obvious phenotype in respect to total 
MHC class I expression in a TAPBPR-depleted cell. Nevertheless, the fact that, in cells over-
expressing TAPBPR, surface expression of MHC class I is reduced, further argues against 
TAPBPR as a peptide loader. But as the loading of high-affinity peptide onto MHC class I is 
such a crucial event in mounting an efficient immune response, it seems intuitively unlikely 
that the single protein tapasin would assume this role. Other proteins could be envisaged to 
operate under conditions such as viral infection and cellular transformation, in which 
components of the antigen processing and presentation pathway are down-regulated in the 
course of immune evasion. 
 
2. TAPBPR could represent a novel sequential step in the classical antigen presentation 
pathway 
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A second possibility to consider is that TAPBPR represents a sequential step in the classical 
MHC class I secretory pathway i.e. tapasin and TAPBPR represent consecutive steps in the 
same pathway (Figure 3B). The strongest data supporting this idea is our finding that 
TAPBPR prolongs the association of MHC class I with the PLC, despite TAPBPR itself not 
associating with the PLC (86). This is consistent with an influence of TAPBPR directly on 
the classical antigen presentation pathway, as opposed to some novel independent pathway. 
Furthermore, TAPBPR slows down the ER export rate of MHC class I, supporting a role for 
it in the conventional secretory pathway for MHC class I (86). In addition, an increased 
association between MHC class I and TAPBPR is observed in tapasin deficient cells, 
suggesting that TAPBPR and tapasin function are somehow intertwined (29).   
 
Our current data intriguingly suggests that TAPBPR may antagonise the function of tapasin. 
First, over-expression of TAPBPR reduces cell surface expression of MHC class I, 
resembling the MHC class I phenotype of a tapasin deficient cell (86).  Second, as mentioned 
above, tapasin and TAPBPR share the same binding site on MHC class I, raising the 
possibility of competition between the two related chaperones (29). However, the relationship 
between tapasin and TAPBPR in the MHC class I pathway appears to be far more complex 
than simple competition, as although the association between TAPBPR and MHC class I is 
increased in the absence of tapasin, no such effect on the association between tapasin and 
MHC I is observed in the absence of TAPBPR (29).  Therefore, much has still to be revealed 
regarding the relationship between tapasin and TAPBPR. Speculation naturally turns to the 
possibility that parallel systems have evolved in the MHC class I and class II system, with the 
function of tapasin and HLA-DM, being regulated by TAPBPR and HLA-DO, respectively 
(89-91).  
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Our data is not particularly supportive of a role of TAPBPR in peptide loading, especially not 
for the majority of the MHC class I population of molecules. Most of the data are more 
consistent with TAPBPR antagonising peptide loading.  Thus, could TAPBPR function as a 
peptide editor or peptide restrictor, somehow monitoring the quality of peptides loaded on 
MHC class I by tapasin?  The reduction in the anterograde trafficking of MHC class I is 
supportive of this, as is the fact that association between TAPBPR and MHC class I is 
enhanced in cells lacking a functional PLC (29, 86).  In this regard, TAPBPR would represent 
a previously uncharacterised quality control step in the MHC class I pathway (Figure 3B). 
Where in the MHC class I pathway would this quality control step be positioned?  The fact 
that TAPBPR binds to a MHC class I heavy chain/ 2m heterodimer in a TAP and tapasin 
independent manner could fit with a role before the PLC. However, given that TAPBPR 
appears to stay associated with MHC class I through the medial Golgi, TAPBPR may 
functions beyond the ER and cis-Golgi (86). In addition to this, the association between 
TAPBPR and MHC class I is enhanced in cells lacking a functional PLC. Thus, we favour a 
location after the PLC, analogous to that identified recently for UGT1 (Figure 3B).  
 
3. TAPBPR could function in the MHC class I cross-presentation pathway 
A third possibility to consider is that TAPBPR plays a role in the MHC class I cross-
presentation pathway (Figure 3C). If this were the case, we would envisage that TAPBPR 
could function as a delivery system, trafficking peptide-receptive MHC class I through the 
secretory pathway and into the endosomal system for peptide loading in endosomes or the 
MHC class II compartment (MIIC). Thus, TAPBPR would be analogous to the invariant 
chain, but for MHC class I molecules.  
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Three essential features of the invariant chain permit its function in the MHC class II 
pathway:1) It blocks MHC class II molecules from picking up peptide in the secretory 
pathway by inserting a segment of itself, the so called class II associated invariant chain 
peptide (CLIP), into the peptide-binding groove of MHC class II (92, 93). 2) It contains 
trafficking motifs in its cytoplasmic tail, which assist in the trafficking of the MHC class II 
molecules into the endosomal system (94-96). 3) In the endosomal environment, it is released 
from the MHC class II molecules, freeing the peptide-receptive MHC class II molecules (97, 
98).  For TAPBPR to be considered analogous to the invariant chain then it should share 
these three properties. Is TAPBPR capable of blocking the peptide-binding groove of MHC 
class I molecules in the ER?  Our current data suggests that TAPBPR may stabilise a peptide-
receptive form of MHC class I but whether TAPBPR is capable of inserting a segment of 
itself into the peptide-binding groove of MHC class I remains to be determined. Does 
TAPBPR contain endosomal trafficking motifs in its cytoplasmic tail?  As mentioned above, 
TAPBPR is not restricted to the ER but transports with MHC class I through the secretory 
pathway (86).  Furthermore, when TAPBPR is over-expressed in HeLa cells it can traffic to 
the cell surface and is internalised into endosomes which contain MHC class I (86). Although 
classical internalisation motifs such as [D/E]xxxL[L/I], YxxΦ, and FxNPxY are not obvious 
in the cytoplasmic tail of TAPBPR, the repertoire of endocytosis motifs is more extensive 
than these three motifs (99).  Thus, TAPBPR could contain an as yet uncharacterised 
trafficking motif or use an alternative mechanism to gain access into the endosomal 
environment.  
One argument against TAPBPR being a missing component in the cross-presentation 
pathway is the fact that it is widely expressed and not exclusively found in cells which cross-
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present, such as DCs.  However, the existence of alternative TAPBPR transcripts containing 
an additional exon in the cytoplasmic region and the finding that these transcripts are 
abundant in dendritic cells as well as peripheral blood mononuclear cells raise the possibility 
that, by producing alternative isoforms, TAPBPR may have access to other subcellular 
compartment in specific cell types (100). 
 
The importance of TAPBPR in human health and disease? 
As TAPBPR is a novel component of the MHC class I antigen processing and presentation 
pathway, and given that it is up-regulated by IFN-γ, it seems very likely that TAPBPR 
contributes to pathogen control, particularly to viral infections. There is also the intriguing 
possibility that TAPBPR might influence immune recognition of tumours and a recent study 
has suggested there is a strong association between TAPBPR expression and glioblastoma 
multiforme patient survival (101). In expression quantitative trait locus (eQTL) studies a 
significant increase in TAPBPR expression level was observed in tumour samples compared 
to organ specific controls and high expression of TAPBPR appeared to be associated with a 
poor outcome (101).    
 
It is worth noting that TAPBPR is polymorphic.  We have currently identified 6 alleles that 
produce nonsynonymous amino acid changes to TAPBPR (Figure 4). Polymorphisms both in 
MHC class I molecules themselves and in specific components of the MHC class I pathway 
are known to strongly influence an individual’s susceptibility to disease. The 
autoinflammatory disease Ankylosing Spondylitis (AS) serves as a classic example of 
polymorphism affecting disease susceptibility.  Not only is AS strongly associated with 
inheritance of a specific HLA-B allomorph, HLA-B27, but polymorphisms in ERAP1, the 
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ER aminopeptidase which trims the peptides presented by MHC class I molecules, have been 
strongly associated with AS (102-104).  Naturally occurring variants of ERAP1 have been 
shown to directly alter protein function, producing molecules that over-trim or under-trim 
peptides (105, 106). Thus peptide handling by HLA-B27 is likely to be important in 
susceptibility to AS (105). Polymorphism in MHC class I is also associated with time to 
onset of AIDS (107). Whether polymorphisms in TAPBPR influence TAPBPR function or 
are influential in susceptibility to autoinflammatory or pathogenic diseases remains to be 
determined. Intriguingly SNPs on chromosome 12p13, adjacent to the TAPBPL gene, are 
associated with AS (105).  
 
CONCLUSIONS 
Although the precise function of TAPBPR in MHC class I pathway remains to be 
determined, its discovery calls for a re-evaluation of the MHC class I antigen processing and 
presentation pathway.  Furthermore, since MHC class I polymorphism is associated with 
clinical illnesses including infectious diseases, autoinflammatory conditions and cancer, it is 
worth considering whether variation in TAPBPR is associated with disease.   
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Figure legends 
Figure 1: The classical MHC class I antigen processing and presentation pathway 
Antigenic peptides (coloured triangles) generated in the cytosol by the proteasome are 
transported into the lumen of the ER by the TAP transporters. Further peptide trimming is 
performed by ERAP1/2. MHC class I heavy chain and β2m are assembled into heterodimers 
by the ER resident chaperones calnexin and calreticulin and then loaded with peptide when 
incorporated into PLC, composed of TAP, tapasin, ERp57 and calreticulin.  UGT1 
reglucosylates MHC I molecules associated with sub-optimal peptide (light blue), thereby 
permitting PLC re-engagement of MHC class I molecules. After loading high affinity peptide 
(dark blue), the MHC class I heterotrimer travel to the cell surface where it is monitored by 
CD8+ T cells. 
 
Figure 2: Comparison of functional domains in tapasin and TAPBPR  
A. Structure of tapasin (PDB ID 3F8U) with residues involved in MHC class I binding 
highlighted in red and C95 highlighted in yellow. B. Homology model of TAPBPR with 
residues involved in MHC class I binding highlighted in red. C. Comparison of 
transmembrane domain and cytoplasmic tail of tapasin and TAPBPR with Lysine 408 and ER 
retention motif KK in tapasin highlighted in red. 
 
Figure 3: Potential function of TAPBPR in the MHC class I antigen presentation 
pathway  
A. TAPBPR could be part of a tapasin-independent folding pathway for MHC class I running 
in parallel to the classical antigen presentation pathway. B. TAPBPR could be a novel 
sequential step in the classical MHC class I antigen presentation pathway, possibly after the 
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PLC in a location analogous to UGT1.   C. TAPBPR could play a role in the MHC class I 
cross-presentation, possibly delivering peptide-receptive MHC class I into the endosomal 
system.  
 
Figure 4: Polymorphisms identified in TAPBPR 
A. Amino acid sequence of TAPBPR (NP_060479.3) with polymorphisms highlighted in 
yellow boxes. B. Homology model of TAPBPR with polymorphic residues highlighted in 
yellow. 
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